Phase I Trial of Fludarabine, Bortezomib and Rituximab for Relapsed and Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma

Based on the hypothesis that bortezomib may potentiate fludarabine activity by inhibiting DNA repair, we designed a phase I trial using this combination with rituximab in patients with relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Twenty-four patients were enrolled. Non-Hodg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Barr, Paul M., Fu, Pingfu, Lazarus, Hillard M., Horvath, Nancy, Gerson, Stanton L., Koc, Omer N., Bahlis, Nizar J., Snell, Michael R., Dowlati, Afshin, Cooper, Brenda W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2827854/
https://ncbi.nlm.nih.gov/pubmed/19656151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07836.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados